Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

POM

Home/Tag:POM
31 10, 2014

Pat’s myeloma therapy plan

Tags: , , , , |10 Comments

Thank God pomalidomide is working for me!  But what do we do once it's not?  Dr. Roy and I had a chance to discuss that on Monday. First the good news.  Dr. Roy's gut feeling is that POM should work well for quite some time.  And statistics back him up.  Patients that respond like I

17 04, 2013

What took so long? Pomalidomide time-line raises questions–I have answers (Part Three)

Tags: , , , , , , , , , |5 Comments

I stuck with the original heading for the third installment of my three part investigative expose'.  But today's post could have been titled, "Different shades of grey."   Pomalidomide's development was shaped by a convoluted system that does a poor job balancing patient need with investor returns. But I'm getting ahead of myself.  Yesterday I promised

9 02, 2013

Everything you always wanted to know about POM but were afraid to ask…

Tags: , , , , , , , , , , , , |4 Comments

The internet is flooded with excitement following the FDA's limited approval of celgene's newest IMiD, pomalidomide (trade name, POMALYST).  POM is an analogue of thalidomide (trade name, Thalomid).  Researchers actually developed POM before Revlimid, but sat on it for a decade--choosing to intensify clinical study activity recently, culminating in yesterday's FDA approval. I'm going to

8 02, 2013

Celgene: FDA approval of POM “based on response rate.”

Tags: , , , , , |7 Comments

Here's Celgene's official press release about today's FDA approval of pomalidomide.  I will review what the news means to me--and my fellow patients and caregivers--this weekend. U.S. FOOD AND DRUG ADMINISTRATION APPROVES POMALYST® (POMALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA SUMMIT, NJ – (Feb. 8, 2013) – Celgene Corporation (NASDAQ: